Summary
As the name suggests, the blood-brain barrier (BBB) tightly controls access to our brains, allowing nutrients and essential substances through, but blocking pathogens, for example. Getting medicines through this protective shield is a major challenge for drug developers, particularly those developing biopharmaceuticals, which are based on large molecules like proteins and antibodies. The goal of IM2PACT is to advance our understanding of the BBB to facilitate the development of more effective treatments for a range of neurological and metabolic disorders. Specifically, the project aims to develop better models of the BBB so that researchers can study it more easily; investigate the biology of the BBB in both health and disease, and the transport routes across it; and to develop innovative systems capable of delivering medicines to the brain. The project will focus on two major disease areas: neurodegenerative diseases, including Alzheimer and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease and motor neurone disease), vascular dementia, and multiple sclerosis; and metabolism-related diseases (mainly diabetes and obesity).
Achievements & News
April 2024
A new peer-reviewed paper used methods developed in the IM2PACT project to show that brain endothelial cells are enriched in...
Participants
Show participants on mapEFPIA companies
- Fujifilm Cellular Dynamics Inc, Madison, United States
- H. Lundbeck As, Valby, Denmark
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Novartis Pharma AG, Basel, Switzerland
- Novo Nordisk A/S, Bagsvaerd, Denmark
- Pfizer Limited, Sandwich, Kent , United Kingdom
- Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
- Aarhus Universitet, Aarhus C, Denmark
- Academisch Ziekenhuis Leiden, Leiden, Netherlands
- Ait Austrian Institute Of Technology GMBH, Wien, Austria
- Cardiff University, Cardiff, United Kingdom
- Kobenhavns Universitet, Copenhagen, Denmark
- Medizinische Universitaet Wien, Vienna, Austria
- Ruprecht-Karls-Universitaet Heidelberg, Heidelberg, Germany
- Stichting Amsterdam Umc, Amsterdam, Netherlands
- Stiftung Tieraerztliche Hochschule Hannover, Hannover, Germany
- The Open University, Milton Keynes, United Kingdom
- The University Of Sheffield, Sheffield, United Kingdom
- Universita Degli Studi Di Modena E Reggio Emilia, Modena, Italy
- Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Wuerzburg, Germany
- Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany
- University Of Dundee, Dundee, United Kingdom
- University of Oxford, Oxford, United Kingdom
- Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Artemis Bio-Support B.V., Utrecht, Netherlands
- Mimetas BV, Leiden, Netherlands
- Neuway Pharma GMBH, Bonn, Germany
- Pharmacoidea Fejleszto Es Szolgaltato Kft, Szeged, Hungary
Participants | |
---|---|
Name | EU funding in € |
Aarhus Universitet | 553 966 |
Academisch Ziekenhuis Leiden | 297 500 |
Ait Austrian Institute Of Technology GMBH | 403 694 |
Artemis Bio-Support B.V. | 290 380 |
Cardiff University | 326 110 |
Kobenhavns Universitet | 602 199 |
Medizinische Universitaet Wien | 208 599 |
Mimetas BV | 251 813 |
Neuway Pharma GMBH | 112 500 |
Pharmacoidea Fejleszto Es Szolgaltato Kft | 300 059 |
Ruprecht-Karls-Universitaet Heidelberg | 290 188 |
Stichting Amsterdam Umc | 290 438 |
Stiftung Tieraerztliche Hochschule Hannover | 290 313 |
The Open University | 232 284 |
The University Of Sheffield | 249 305 |
Universita Degli Studi Di Modena E Reggio Emilia | 67 565 |
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat | 293 719 |
Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz | 288 661 |
University Of Dundee | 354 009 |
University of Oxford | 2 183 451 |
Uppsala Universitet | 1 113 250 |
Total Cost | 9 000 003 |